Substituted Quinoline SOS1 Inhibitors for KRAS Mutation Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers with KRAS or SOS1 mutations, such as lung and pancreatic cancer, lack effective drugs that can inhibit SOS1 activity to block RAS activation, leading to limited therapeutic options for patients, especially those with chemotherapy-resistant cases.
Innovation Solution
Development of novel substituted quinoline-based compounds that act as SOS1 inhibitors, capable of disrupting the RAS-SOS1 interaction, which are administered as pharmaceutical compositions to treat various cancers, including breast, lung, pancreatic, and colorectal cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for cancers with KRAS or SOS1 mutations, then current chemotherapy options are available, but therapeutic effectiveness is limited and patients with chemotherapy-resistant cases have no effective treatment
Solution Approach 1:
The patent applies parameter changes by developing novel substituted quinoline-based compounds with specific molecular structures (Formula 1) that exhibit SOS1 inhibition activity. The chemical parameters of the treatment agent are changed from conventional chemotherapy drugs to SOS1 inhibitors, enabling effective treatment of cancers with KRAS or SOS1 mutations that are resistant to traditional chemotherapy.
2Reliability
If SOS1 inhibition activity is developed to block RAS activation, then therapeutic effectiveness for KRAS/SOS1 mutation cancers is improved, but drug development complexity and time increase
Solution Approach 1:
The patent applies segmentation by identifying and targeting the specific SOS1-RAS interaction interface. The substituted quinoline-based compounds are designed to selectively bind to SOS1 and disrupt its interaction with RAS, segmenting the therapeutic approach from general chemotherapy to targeted molecular inhibition. This focused mechanism reduces development complexity compared to developing entirely new broad-spectrum anticancer agents.
Solution Approach 2:
The patent uses the substituted quinoline-based compound as an intermediary molecule that mediates between the SOS1 enzyme and RAS protein. The compound acts as a molecular mediator that binds to SOS1 and prevents the SOS1-RAS interaction, thereby blocking RAS activation without requiring direct modification of the RAS protein itself.
3Adaptability or versatility
If novel substituted quinoline-based compounds are developed as SOS1 inhibitors, then new therapeutic mechanisms are provided for chemotherapy-resistant cancers, but manufacturing and clinical validation requirements increase
Solution Approach 1:
The patent applies universality by designing substituted quinoline-based compounds (Formula 1) with a core structure that provides SOS1 inhibition activity while allowing for various substitutions (R1, R2, R3, R4, R5 groups) to optimize different properties. This modular design enables a single platform compound to be adapted for multiple cancer types and resistance profiles, reducing the need to develop entirely new molecules for each clinical scenario.
Data Source
AI summary
The present disclosure relates to novel SOS1 inhibitors, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.